5 recruiting, 2 not yet recruiting. 4 Phase 3, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Not yet recruiting 1 |
| Not applicable | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Resilience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes Edra PRO - Mood Disorder (Depressive Episodes) | Not applicable | Recruiting | Resilience | 594 | 2025-10-31 | 2026-05-01 |
| Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC) Remote symptoms moniotring - Head and Neck Squamous Cell Carcinoma HNSCC | Not applicable | Recruiting | Centre Henri Becquerel | 192 | 2025-10-15 | 2025-12-30 |
| A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer multimodal Resilience© digital companion, Standard supportive care - Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 180 | 2025-09-09 | 2025-12-01 |
| Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy GutyCare - IBD | Phase 3 | Not yet recruiting | Resilience | 116 | 2025-06-01 | 2025-06-29 |
| Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only Resilience PRO - Cancer | Phase 3 | Recruiting | Resilience | 1458 | 2025-04-01 | 2026-04-03 |
| CARE1 Pragmatic Clinical Trial Nivolumab, Ipilimumab, Pembrolizumab - Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 1250 | 2024-04-12 | 2025-01-16 |
| Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma ONCOLAXY Follow-up - Diffuse Large B Cell Lymphoma | Not applicable | Not yet recruiting | Weprom | 160 | 2022-07-01 | 2022-04-05 |
Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Mood Disorders (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Axitinib (1) · Ipilimumab (1) · Nivolumab (1) · cabozantinib (1) · lenvatinib (1) · pembrolizumab (1)
France (6) · Austria (1) · Czechia (1) · Germany (1) · Netherlands (1)
Antoine Yrondi, MD, PhD (1) · Sebastien Thureau, MD,PhD (1)
2023 (1)